Cook Medical's Zilver stent shines with three-year data; Doctor accused of submitting false device data;

 @FierceMedDev: As BSX has implied, the job cuts are coming. More | Follow @FierceMedDev

 @MarkHFierce: Not only is angel investing recovering, but much of it seems to be hitting medical device startups. More | Follow @MarkHFierce

 @DamianFierce: Four former Synthes execs have been effectively blacklisted from the life sciences industry. More | Follow @DamianFierce

> Cook Medical is touting three-year data for its Zilver PTX stent, designed to treat femoropopliteal disease. The device is pending FDA approval. More

> A new study finds that Second Sight Medical Products' Argus II retinal implant helped a majority of blind patients identify motion. The device recently won an approval recommendation from an FDA panel. News

> Last month, the FDA rejected Navidea Biopharmaceuticals' ($NAVB) application for the diagnostic aid Lymphoseek. Now, the company says it has met with the agency and will address the third-party manufacturing issues that halted its first application. Statement

> Quanterix said its single molecule digital diagnostic test appears to detect HIV with much more sensitivity than conventional immunoassays. Release

> IBA, a Belgian cancer diagnosis and therapy company, has sold nearly $13 million worth of specialized sterilization units as part of three separate deals in Asia. Story

> A doctor in the United Kingdom is accused of knowingly submitting false data in a trial involving NMT Medical's StarFlex device to treat migraines. Item

> Amarantus BioSciences has acquired an option to license the the LymPro Alzheimer's Diagnostic Blood Test from Memory Dx (formerly Provista Life Sciences). The test, initially developed in Germany is ready to advance into Phase II trials. Release

Biotech News

 @FierceBiotech: New special report: Top diabetes drug pipelines of 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: Kythera IPO prices at high end of range (I don't write that very often). More | Follow @JohnCFierce

 @RyanMFierce: GSK will decide whether to grant access to the ID-less patient data based on scientific merit. Sounds subjective, but progress nonetheless. | Follow @RyanMFierce

> Sanofi argues its R&D costs are too high, but backs down on Toulouse. Story

> Will GlaxoSmithKline's transparency pledge force pharma rivals to open up? Article

Pharma News

@FiercePharma: India's pharma industry is the country's 2nd-best at making billionaires. More | Follow @FiercePharma

> Another compounding group shuts amid outbreak. Article

> Glaxo pledges to unveil all trial data, good, bad or ugly. Item

> Minister: Jobs at Sanofi's Toulouse site mostly safe. Story

Pharma Manufacturing News

> Novasep investing in another API expansion. News

> Auctus Pharma API plant in India catches fire. Report

> Merck opens $21M Jakarta packaging plant. Story

Vaccines News

> GSK, Aeras partner for TB vaccine trial. More

> Merck taps Vaxxas for Nanopatch vaccine delivery. Story

> Pfizer's Prevnar 13 posts positive late-stage data. Report

> Takeda snaps up LigoCyte for $60M. Item

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.